Skip to content
MARKETS / NASDAQ / FEMY
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Femasys Inc. FEMY

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.3M
▲ 40.8% YoY
$-18.6M
$-19.2M
In brief

What this company does

The Company is a U.S. manufacturer that has received global regulatory approvals for its product portfolio, which is currently being commercialized in the U.S. and key international markets. Femasys Inc. was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. As of December 31, 2025, we employed 51 full-time employees and 3 part-time employees.

Written from the business description in Femasys Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 2.3M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 2.3 · Net income -18.6
0.8M1.6M-8.0M-16.0M202020212022202320242025
Compound annual growth
+23.9%
+17.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +17.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−812 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -767.0% · Net -812.3%
-500%-1000%202020212022202320242025
ROE
FY2025 · ROE -455.8%
-200%-400%202020212022202320242025

Each USD of equity lost 456 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -19.2
-8M-16M202020212022202320242025
Net buybacks $M Dividends $M
FY2024 · Dividends — · Net buybacks -2.0
-2.5M-5.0M202220232024

Total assetsUSD 20.7M
EquityUSD 5.9M
CashUSD 9.3M
Current ratio4.53×

Equity funds 28% of total assets.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020
Revenue $B0.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.47−0.85−0.93−0.96−1.12−7.20
Dividend / sh $······
Payout %······
ROE %−455.8−182.2−84.8−54.8··
Shares out B0.060.020.020.010.010.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 27 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 65 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2020

Share this section

Download image